SPG7 is an autosomal recessive hereditary neurodegenerative disease, manifesting as spastic ataxia typically in adulthood.2 Although currently no curative treatment exists, progress in the development of genomic therapies for genetic spastic ataxias, including antisense oligonucleotides and gene replacement strategies, and first treatment trials conducted in diseases such as spastic paraplegia type 50 (SPG50, NCT05518188) or spinocerebellar ataxia types 1 and 3 (SCA1/SCA3, NCT05822908) raises hopes that potential therapeutic agents for SPG7 might become available in the near future. The gene discussed is ATXN3; the disease is spinocerebellar ataxia type 1.